Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

52results about How to "Reduced risk of degradation" patented technology

A continuous fiber 3D printing device and method

ActiveCN108297404BReduce damage rateControl the problem of "forced migration after laying in situ"Manufacturing enclosuresManufacturing heating elementsFiberEngineering
The invention provides a continuous fiber 3D printing device and a continuous fiber 3D printing method. The continuous fiber 3D printing device comprises a fiber roller, a gumming part and a printingpart; the gumming part is provided with a housing injected with a resin solution; a tension roller, a gumming opposite-opening roller and a traction roller are sequentially arranged in the housing; the tension roller is arranged above a liquid level of the resin solution and is used to provide dry fiber with a part of pre-tightening force by the action of frictional force; the gumming opposite-opening roller is arranged below the liquid level of the resin solution; the gumming opposite-opening roller and the tension roller form an included angle; the traction roller is arranged above the liquid level of the resin solution and is used to provide traction force; and the dry fiber enters into the gumming part through the fiber roller, is gummed by the tension roller, the gumming opposite-opening roller and the traction roller sequentially, and then is printed by the printing part. The intensity of an obtained workpiece is improved by more than 4 times compared with that of a workpiece in3D printing of existing resin, so that a foundation is laid for high-performance printing components applied to the aerospace field.
Owner:AEROSPACE INST OF ADVANCED MATERIALS & PROCESSING TECH

Low-temperature high-yield single subunit RNA (ribonucleic acid) polymerase, purification method and application

The invention discloses a low-temperature high-yield single subunit RNA (ribonucleic acid) polymerase, namely VSW3RNA polymerase, which is applied to efficient synthesizing of RNA at low temperature.The single subunit RNA polymerase is RNA polymerase expressed by a low-temperature phage VSW-3, and can be used for transcribing and synthesizing RNA by taking DNA (deoxyribonucleic acid) as a template within the temperature range of 4-30 DEG C; when the temperature is 25 DEG C, the efficiency of synthesizing RNA by the VSW3RNA polymerase is the highest, and the yield of the VSW3RNA polymerase even exceeds that of T7RP which is widely applied to RNA in-vitro transcription synthesis at present. A base sequence for coding the enzyme is shown in a sequence table SEQ ID NO. 1, an amino acid sequence of the enzyme is shown in a sequence table SEQ ID NO. 2, and a specific promoter sequence recognized by the enzyme is shown in a sequence table SEQ ID NO. 5. The VSW3RNA polymerase is found to be afirst single subunit RNA polymerase which has RNA synthesis capability comparable to or even superior to that of T7RP, and the most suitable temperature for transcribing and synthesizing RNA is 25 DEG C and is 12 DEG C lower than the transcription temperature of 37 DEG C of T7RP, thus an important enzyme tool is provided for efficiently synthesizing RNA at low temperature, and the increasing requirements of scientific research and medical markets on RNA products can be met.
Owner:RNASYN BIOTECH CO LTD

Method for detecting target microbial genome RNA based on high-throughput sequencing technology

The invention belongs to the technical field of high-throughput sequencing and microbiological detection, and particularly relates to a method for detecting target microbiological genome RNA based on a high-throughput sequencing technology. The method comprises the following steps: carrying out nucleic acid extraction, DNA digestion, RNA purification, RNA fragmentation, inverse transcription synthesis of cDNA molecules, cDNA library construction, high-throughput sequencing and sequencing data analysis on a to-be-detected sample containing a target microorganism, and detecting the condition of the genome RNA of the target microorganism in the sample. In the DNA digestion step, digestion is carried out under mild conditions of incubation at 37 DEG C to 42 DEG C for 10 to 30 minutes using a DNA enzyme, and further, in the RNA fragmentation step, a thermal disruption means is used. According to the method, due to the adoption of a mild digestion means and a thermal interruption means, the microbial genome RNA can be efficiently and quickly enriched at low cost, the content of the microbial genome RNA is increased, and the success rate of constructing an RNA high-throughput sequencing library is increased, so that the detection sensitivity of the microbial genome RNA is improved.
Owner:深圳华大因源医药科技有限公司 +2

Long-acting pharmaceutical preparation combination of leuprolide acetate and use method of pharmaceutical preparation combination

The invention belongs to the technical field of pharmaceutical preparation, and in particular relates to a long-acting pharmaceutical preparation combination of leuprolide acetate and a use method ofthe pharmaceutical preparation combination. The long-acting pharmaceutical preparation combination of leuprolide acetate of the invention comprises separately independently stored leuprolide acetate or analogues of leuprolide acetate, biodegradable polymer microspheres and solvents; and the biodegradable polymer microspheres are microspheres formed by a mixture of PLGA and PCL. According to the present invention, by adopting the pharmaceutical preparation combination, the glass transition temperature of the polymer is reduced, the burst release of the drug at the beginning of release is reduced, and the yield of the biodegradable polymer microspheres is improved; the risk of polymer degradation during storage is reduced, the temperature of storage and transportation is also reduced, and the cost of storage and transportation is saved; and the problems that the drug loading of leuprolide acetate microspheres can not be increased and the burst release of the prior leuprolide acetate gel(Eligard) is too large are solved.
Owner:SHANDONG GUYUCHUN BIOTECHNOLOGY CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products